Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ainos, Inc. - warrants (NQ: AIMDW )

0.0260 UNCHANGED
Last Price Updated: 9:30 AM EDT, Oct 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0260
Bid (Size) 0.0270 (1)
Ask (Size) 0.0594 (11)
Prev. Close 0.0260
Today's Range 0.0260 - 0.0260
52wk Range 0.0250 - 0.5730
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
Via ACCESSWIRE
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
Via ACCESSWIRE

Performance

YTD
-85.43%
-85.43%
1 Month
-48.00%
-48.00%
3 Month
-62.86%
-62.86%
6 Month
-53.74%
-53.74%
1 Year
-93.33%
-93.33%

More News

Read More
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
Via ACCESSWIRE
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Via ACCESSWIRE
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
Via ACCESSWIRE
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
Via ACCESSWIRE
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter
Via ACCESSWIRE
Ainos Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Ainos Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
Via ACCESSWIRE
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Via ACCESSWIRE
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
Via ACCESSWIRE
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
Via ACCESSWIRE
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
Via ACCESSWIRE
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
Via ACCESSWIRE
Ainos Reports Full Year 2023 Financial Results
Via ACCESSWIRE
Ainos Announces $1.75 Million Follow-On Funding
Via ACCESSWIRE
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
Via ACCESSWIRE
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
Via ACCESSWIRE
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Via ACCESSWIRE
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
From Virtual Investor Conferences
Via GlobeNewswire
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESSWIRE
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
Via ACCESSWIRE
Ainos, Inc. Announces Stock Consolidation
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.